Welcome to Gentronix
Gentronix provides services and solutions to help organisations optimise the development of drugs and other chemicals, by testing for genotoxicity, across a wide range of chemistry driven industries.
Gentronix offers classical Ames and Micronucleus genotoxicity assays plus GreenScreen®HC and BlueScreen™HC; our novel, patented systems that detect all known classes of genotoxin. Gentronix can provide assays and advice on follow-up strategies for mechanism elucidation to help chemists modify compounds to eliminate genotoxicity early in product discovery and development.
Gentronix is GLP compliant and offers regulatory assays to OECD and other test guidelines.
Latest News Subscribe to our newsletter
Privacy Notice Update
Gentronix has published an updated privacy notice in the light of changes to data protection regulations in the EU (GDPR).
Gentronix now offers non-GLP Ames Bacterial Reverse Mutation Screening Assay Gentronix is now able to offer 5-strain full Ames screening that is compliant with OECD Guideline 471. Because formulation analysis…
Lundbeck outlines its strategy for “Exploratory toxicology as an integrated part of drug discovery” Scientists at the Danish pharmaceutical company H. Lundbeck A/S have published two papers, in the January 2014 issue of the…
Gentronix now offers the in vivo micronucleus testing of rodent blood samples using flow cytometry Gentronix, specialists in genotoxicity testing, now offers in vivo Micronucleus testing of rodent blood samples using flow cytometry. The rodent peripheral blood…